Last reviewed 2026-04-22 · How we verify

CS-3150

CS-3150 is a non-steroidal mineralocorticoid receptor (MR) antagonist that blocks aldosterone signaling to reduce sodium retention and blood pressure.

CS-3150 is a non-steroidal mineralocorticoid receptor (MR) antagonist that blocks aldosterone signaling to reduce sodium retention and blood pressure. Used for Hypertension, Heart failure with preserved ejection fraction (HFpEF).

At a glance

Mechanism of action

CS-3150 selectively antagonizes the mineralocorticoid receptor, preventing aldosterone-mediated sodium reabsorption and potassium excretion in the kidney. This leads to natriuresis, reduced fluid volume, and decreased blood pressure. It is designed to have improved selectivity for the MR over other steroid receptors compared to earlier-generation MR antagonists, potentially reducing off-target effects.

Approved indications

• Hypertension
• Heart failure with preserved ejection fraction (HFpEF)

Common side effects

• Hyperkalemia
• Headache
• Dizziness
• Diarrhea

Key clinical trials

• A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects (PHASE2)
• A Phase 2 Exploratory Study of CS-3150 in Japanese Hypertensive Patients With Moderate Renal Impairment (PHASE2)
• Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension (PHASE3)
• The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers (PHASE1)
• Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension (NA)
• Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria (PHASE3)
• Study of CS-3150 in Patients With Essential Hypertension (PHASE3)
• Study of CS-3150 in Patients With Severe Hypertension (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.